Details werden geladen...
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models | The Manila Times
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models
Ähnliche Seiten
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia | The Manila Time...
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/design-therapeutics-announces-four-week-iv-data-from-the-restore-fa-trial-of-dt-216p2-demonstrating-clinical-improvements-and-comprehensive-biomarker-activity-in-friedreich-ataxia/2346077Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/alaunos-reports-preclinical-aln1003-data-showing-effects-on-insulin-resistance-related-biomarkers-and-liver-histology-in-diet-induced-obesity-models/2346185Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/immuneering-reports-173-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy/2349698
Akari Therapeutics (AKTX) Stock Skyrockets 120% on Promising Cancer Drug Results - Blockonomi
https://blockonomi.com/akari-therapeutics-aktx-stock-skyrockets-120-on-promising-cancer-drug-results/Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/byondis-establishes-scientific-advisory-board-of-recognized-leaders-in-oncology-research-and-adc-development/2345860